Skip to content

Study · Animal study (in vivo) · mouse · 2003

11 results

Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.

Getting SJ, Schiöth HB, Perretti M

The Journal of pharmacology and experimental therapeutics15 May 2003Cited by 32 (Europe PMC)

PMID12750433 (opens in a new tab)DOI10.1124/jpet.103.051623 (opens in a new tab)PepBankPUB-12750433
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with crystal-induced peritonitis, systemic KPV significantly reduced polymorphonuclear leukocyte accumulation in the peritoneal cavity.

    In plain wordsIn mice with induced peritonitis, KPV given by injection reduced the build-up of white blood cells in the abdomen.

    Peptide
    KPV
    Outcome
    DecreaseNeutrophil accumulation in peritoneal cavity (crystal-induced peritonitis)
    Study

    mousen: not reported in source

    crystal-induced peritonitis
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Systemic treatment of mice with KPV, alpha-MSH, the core melanocortin peptide His-Phe-Arg-Trp, and the melanocontin receptor 3/4 agonist Ac-Nle4-c[Asp5,d-Phe7,Lys10]NH2 ACTH4-10 (MTII) but not the selective MC1-R agonist H-Ser-Ser-Ile-Ile-Ser-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (MS05) resulted in a…
    1 context sentence
    Summary · context
    In this study, we analyzed the anti-inflammatory effects of alpha-melanocyte stimulating hormone (MSH)11-13 (KPV) in comparison with other MSH peptides in a model of crystal-induced peritonitis.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice, the antimigratory effect of KPV was not blocked by the MC3/4-R antagonist SHU9119.

    In plain wordsIn mice, a compound that blocks two melanocortin receptors did not stop KPV from limiting white blood cell movement.

    Peptide
    KPV
    Outcome
    DecreaseAntimigratory effect of KPV with MC3/4-R antagonist SHU9119
    Study

    mousen: not reported in source

    crystal-induced peritonitis
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The antimigratory effect of KPV was not blocked by the MC3/4-R antagonist Ac-Nle4-c[Asp5,d-2Nal7,Lys10]NH2 ACTH4-10 (SHU9119).
    1 context sentence
    Summary · context
    In this study, we analyzed the anti-inflammatory effects of alpha-melanocyte stimulating hormone (MSH)11-13 (KPV) in comparison with other MSH peptides in a model of crystal-induced peritonitis.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    KPV had anti-inflammatory effects in mice with IL-1beta-induced peritonitis.

    In plain wordsIn mice, KPV reduced inflammation in peritonitis caused by IL-1beta.

    Peptide
    KPV
    Outcome
    DecreaseInflammation in IL-1beta-induced peritonitis
    Study

    mousen: not reported in source

    IL-1beta-induced peritonitis
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The anti-inflammatory properties of KPV were also evident in IL-1beta-induced peritonitis inflammation
    1 context sentence
    Summary · context
    In this study, we analyzed the anti-inflammatory effects of alpha-melanocyte stimulating hormone (MSH)11-13 (KPV) in comparison with other MSH peptides in a model of crystal-induced peritonitis.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    The anti-inflammatory properties of KPV were also evident in mice with a nonfunctional MC1-R.

    In plain wordsIn mice lacking a working MC1 receptor, KPV still showed anti-inflammatory effects.

    Peptide
    KPV
    Outcome
    DecreaseInflammation in mice with nonfunctional MC1-R
    Study

    mousen: not reported in source

    recessive yellow (e/e) mice with nonfunctional MC1-R
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The anti-inflammatory properties of KPV were also evident
    2 context sentences
    Summary · context
    in mice with a nonfunctional MC1-R (recessive yellow e/e mice).
    Summary · context
    In this study, we analyzed the anti-inflammatory effects of alpha-melanocyte stimulating hormone (MSH)11-13 (KPV) in comparison with other MSH peptides in a model of crystal-induced peritonitis.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with crystal-induced peritonitis, systemic MTII significantly reduced accumulation of polymorphonuclear leukocytes in the peritoneal cavity.

    In plain wordsIn mice with crystal-induced peritonitis, melanotan II (MTII) reduced the build-up of white blood cells in the abdominal cavity.

    Peptide
    Melanotan II
    Outcome
    DecreasePolymorphonuclear leukocyte accumulation in the peritoneal cavity
    Study

    mousen: not reported in source

    Crystal-induced peritonitis
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Systemic treatment of mice with KPV, alpha-MSH, the core melanocortin peptide His-Phe-Arg-Trp, and the melanocontin receptor 3/4 agonist Ac-Nle4-c[Asp5,d-Phe7,Lys10]NH2 ACTH4-10 (MTII)
    2 context sentences
    Summary · context
    resulted in a significant reduction in accumulation of polymorphonuclear leukocyte in the peritoneal cavity.
    Summary · context
    In this study, we analyzed the anti-inflammatory effects of alpha-melanocyte stimulating hormone (MSH)11-13 (KPV) in comparison with other MSH peptides in a model of crystal-induced peritonitis.
  6. 06LabIn vitro (cells)Mechanism

    In vitro, KPV did not inhibit macrophage release of KC, unlike alpha-MSH and MTII.

    In plain wordsIn cells, KPV did not reduce KC release from activated macrophages, unlike alpha-MSH and MTII.

    Peptide
    KPV
    Outcome
    No significant changeKC release from activated macrophages
    Study

    n: not reported in source

    macrophages in vitro
    Comparator
    alpha-MSH and MTII
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, macrophage activation, determined as release of KC and interleukin (IL)-1beta was inhibited by alpha-MSH and MTII but not by KPV.
    1 context sentence
    Summary · context
    In this study, we analyzed the anti-inflammatory effects of alpha-melanocyte stimulating hormone (MSH)11-13 (KPV) in comparison with other MSH peptides in a model of crystal-induced peritonitis.
  7. 07LabIn vitro (cells)Mechanism

    In vitro, KPV did not inhibit macrophage release of interleukin-1beta, unlike alpha-MSH and MTII.

    In plain wordsIn cells, KPV did not reduce interleukin-1beta release from activated macrophages, unlike alpha-MSH and MTII.

    Peptide
    KPV
    Outcome
    No significant changeIL-1beta release from activated macrophages
    Study

    n: not reported in source

    macrophages in vitro
    Comparator
    alpha-MSH and MTII
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, macrophage activation, determined as release of KC and interleukin (IL)-1beta was inhibited by alpha-MSH and MTII but not by KPV.
    1 context sentence
    Summary · context
    In this study, we analyzed the anti-inflammatory effects of alpha-melanocyte stimulating hormone (MSH)11-13 (KPV) in comparison with other MSH peptides in a model of crystal-induced peritonitis.
  8. 08LabIn vitro (cells)Mechanism

    KPV failed to increase cAMP accumulation in macrophages, whereas MTII increased it.

    In plain wordsIn cells, KPV did not raise cAMP in macrophages, whereas MTII did.

    Peptide
    KPV
    Outcome
    No significant changecAMP accumulation in macrophages
    Study

    n: not reported in source

    macrophages in vitro
    Comparator
    MTII
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    whereas KPV failed to increase cAMP.
    2 context sentences
    Summary · context
    macrophage activation by MTII led to an increase in cAMP accumulation
    Summary · context
    In this study, we analyzed the anti-inflammatory effects of alpha-melanocyte stimulating hormone (MSH)11-13 (KPV) in comparison with other MSH peptides in a model of crystal-induced peritonitis.
  9. 09LabIn vitro (cells)Mechanism

    In cultured macrophages, MTII inhibited the release of KC during macrophage activation.

    In plain wordsIn cells, melanotan II (MTII) reduced the release of the inflammatory signal KC by activated macrophages.

    Peptide
    Melanotan II
    Outcome
    DecreaseKC release from activated macrophages
    Study

    n: not reported in source

    Macrophages
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, macrophage activation, determined as release of KC and interleukin (IL)-1beta was inhibited by alpha-MSH and MTII but not by KPV.
    1 context sentence
    Summary · context
    In this study, we analyzed the anti-inflammatory effects of alpha-melanocyte stimulating hormone (MSH)11-13 (KPV) in comparison with other MSH peptides in a model of crystal-induced peritonitis.
  10. 10LabIn vitro (cells)Mechanism

    In cultured macrophages, MTII inhibited the release of interleukin-1beta during macrophage activation.

    In plain wordsIn cells, melanotan II (MTII) reduced the release of the inflammatory signal interleukin-1beta by activated macrophages.

    Peptide
    Melanotan II
    Outcome
    DecreaseIL-1beta release from activated macrophages
    Study

    n: not reported in source

    Macrophages
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, macrophage activation, determined as release of KC and interleukin (IL)-1beta was inhibited by alpha-MSH and MTII but not by KPV.
    1 context sentence
    Summary · context
    In this study, we analyzed the anti-inflammatory effects of alpha-melanocyte stimulating hormone (MSH)11-13 (KPV) in comparison with other MSH peptides in a model of crystal-induced peritonitis.
  11. 11LabIn vitro (cells)Mechanism

    In macrophages, MTII increased cAMP accumulation, and the MC3/4 receptor antagonist SHU9119 attenuated this increase.

    In plain wordsIn cells, melanotan II (MTII) raised cAMP in macrophages, and a receptor blocker reduced this rise.

    Peptide
    Melanotan II
    Outcome
    IncreasecAMP accumulation in macrophages
    Study

    n: not reported in source

    Macrophages
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, macrophage activation by MTII led to an increase in cAMP accumulation, which was attenuated by SHU9119, whereas KPV failed to increase cAMP.
    1 context sentence
    Summary · context
    In this study, we analyzed the anti-inflammatory effects of alpha-melanocyte stimulating hormone (MSH)11-13 (KPV) in comparison with other MSH peptides in a model of crystal-induced peritonitis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 39Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:04 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:03 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.